All issues
Volume 168 (1992)
- Issue 4 Pages 539-
- Issue 3 Pages 449-
- Issue 2 Pages 67-
- Issue 1 Pages 1-
Volume 168, Issue 2
Displaying 51-61 of 61 articles from this issue
-
YONG S. CHUNG, TETSUJI SAWADA, YASUYUKI KONDO, Jenny J.L. HO, YOUNG S. ...1992 Volume 168 Issue 2 Pages 397-401
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSCHUNG, Y.S., SAWADA, T., KONDO, Y., HO, J.J.L., KIM, Y.S. and SOWA, M. Tumor Localization and Biodistribution with Radiolabeled Monoclonal Antibody against Pancreatic Cancer in Tumor-Bearing Nude Mice. Tohoku J. Exp. Med., 1992, 168 (2), 397-401- Nd2 is a murine monoclonal antibody produced against a mucin fraction purified from xenografts of a human pancreatic cancer cell line SW1990. Immunoperoxidase staining showed that the antigen recognized by Nd2 was psesent in 82.9% of pancreatic cancer tissues but not in tissues of normal pancreas and chronic pancreatitis. However Nd2 antigen was found not to be elevated in the sera of patients with pancreatic cancer. Four days after injection of 111In-Nd2 into athymic nude mice bearing SW1990 xenograft there was a higher accumulation in the tumor compared to 111In-normal mouse IgG1. When these mice were scanned with a gamma camera, labeled Nd2 was shown to accumulate in the tumor rapidly on the 1st day after injection and by the 4th day tumor accumulation was more distinctly visualized than non-specific accumulation in liver. These results indicate that Nd2 has high specificity and reactivity for pancreatic cancer and may have possible applicants in radioimmunodetection or targeting of therpeutic drugs in pancreatic cancer.- Nd2; murine monoclonal antibody; immunoperoxidase reaction human pancreatic cancer cells SW 1990; radioimmunodetectionView full abstractDownload PDF (453K) -
KIKUYOSHI YOSHIDA, TAKEHIKO TACHIBANA1992 Volume 168 Issue 2 Pages 403-407
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSYOSHIDA, K. and TACHIBANA, T. A Possible Role of Activated Macrophages in the Adoptive Immunotherapy Using CD4+ T Lymphocytes. Tohoku J. Exp. Med., 1992, 168 (2), 403-407- Potent anti-tumor T lymphocytes with CD4+8- phenotype were obtained in peritoneal exudate cells by immunizing mice with irradiated tumor cells and OK-432. These effector cells were used in adoptive immunotherapy for tumor-bearing mice. Admixed administration of effector T cells with irradiated relevant tumor cells resulted in a marked enhancement of anti-tumor activity against local tumor and lymph node metastasis compared with the immunotherapy by effectors alone. The activating state of macrophages inoculated with viable tumor cells had much relevance with the implementation of immunotherapy. Innocent bystander lysis was not observed in this imunotherapy. Interleukin-2 given instead of stimulant tumor cells caused no enhancement, while interleukin-1 emerged stronger enhancement than stimulant tumor. In this case, activating state of macrophages had no relevance with the effectiveness of the therapy. These results suggest that macrophages in tumor play a role to secrete interleukin-1 to enhance anti-tumor activity of specific T cells.- CD4+ T lymphocyte; adoptive immunotherapy; macrophage; interleukin-1; lymph node metastasisView full abstractDownload PDF (439K) -
HIROSHI OGURI, YOSHIHARU SATO, HIROMITSU SUGAWARA, KIKUYOSHI YOSHIDA, ...1992 Volume 168 Issue 2 Pages 409-412
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSOGURI, H., SATO, Y., SUGAWARA, H., YOSHIDA, K., NISHIHIRA, T., MORI, S. and TACHIBANA, T. The Difference in Immunological Properties between Lymph Node Metastatic and Non-Metastatic Cell Lines of MCA-Induced Fibrosarcoma of C4W Mice. Tohoku J. Exp. Med., 1992, 168 (2), 409-412- To pursure the process of lymph node metastasis, i.e, the preferential tumor growth in lymph node, we have established the non-metastatic M2B cell line which was derived from 3- methylcholanthrene-induced fibrosarcoma of C4W mouse and a metastatic cell line, M2BLN-M+ which was obtained from metastatic lymph nodes of irradiated C4W mouse which was subcutaneously implanted with cultured tumor cells, because implanted tumor cells were derived from the spontaneous metastatic lymph node of the parental M2B tumor, but regressed in naive C4W mouse. We examined the characteristics of both tumor cell lines in terms of the immunological cellular interactions. M2BLN-M+ showed unexpectedly to be more susceptible to cytotoxicity of immune effectors (NK cell, macrophage and cytotoxic T lymphocyte) than M2B did. When cultured both tumor cells with these effector cells, the growth inhibition of M2BLN-M+ was greater than that of M2B. The regional lymph node of tumor-bearer, however, showed no effective cytotoxic activity as reported by others. On the contrary, when cultured both tumor cells with non-immune lymph node cells, to be surprised, the proliferation of M2B was markedly suppressed, while that of M2BLN-M+ was slightly inhibited. The lymph node cells of M2B-bearing mice showed stronger cytostatic activity to M2B. The results suggest that the cytostatic activity of lymph node cells will be a pivotal factor, concerning the establishment of lymph node metastasis.- lymph node; metastasis; malignant tumor; cytotoxicity; cytostatic activityView full abstractDownload PDF (344K) -
MASUO HOSOKAWA, YOSHITAKA WAKIZAKA, YASUHIRO KURAMITSU, MARK MICALLEF, ...1992 Volume 168 Issue 2 Pages 413-416
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSHOSOKAWA, M., WAKIZAKA, Y., KURAMITSU, Y., MICALLEF, M., TOGASHI, Y. and KOBAYASHI, H. Augmented Accumulation of Transferred Lymphokine- Activated Killer (LAK) Cells at Murine Tumor Sites through Production of LAK-Attractant Facilitated by Chemotherapy. Tohoku J. Exp. Med., 1992, 168 (2), 413-416- We observed that effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells on BMT-11, a fibrosarcoma in C57BL/6 mice were improved by combination with cyclophosphamide (CY)-chemotherapy corresponding to enhanced accumulation at tumor sites of LAK cells. On the other hand, cytotoxic T lymphocytes (CTLs) which were able to accumulate at tumor sites more densely than LAK cells produced significant therapeutic effects by themselves. We have also found observed that LAK-attractant activity was detected in conditioned medium (CM) of CY-treated tumor tissue but not in the CM of untreated tumor tissue. These findings reveal that CY-chemotherapy facilitates LAK-attractant-production and enhances the accumulation in tumor tissue of LAK cells and that therapeutic effects of adoptive transfer of LAK cells are augmented by cancer chemotherapy through the enhanced accumulation of LAK cells.- lymphokine-activated killer; fibrosarcoma; cytotoxic T lymphocyte; adoptive transfer; cyclophosphamideView full abstractDownload PDF (417K) -
TOMOKO OKUDA, TAKEHIKO TACHIBANA1992 Volume 168 Issue 2 Pages 417-420
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSOKUDA, T. and TACHIBANA, T. The Role of Complement Receptors in Tumor Cell Destruction. Tohoku J. Exp. Med., 1992, 168(2), 417-420 - Murine peritoneal macrophages exuding early after stimulation with the activators of the alternative complement pathway are able to destroy some of the tumor cells. This destruction is inhibited by anti-Mac-1 and anti-C3. The tumor cell killing needs longer incubation time (>15hr), and anti-Mac-1 affects the reaction even if it were put into the reaction mixture at later time of incubation. The results suggest that complement produced by macrophage is deposited onto target cells, and the complement binding targets interact with macrophages through the complement receptor type 3 (CR3), which leads to the cell destruction. It is known that fully activated macrophages kill the tumor cells with the aid of antibody (ADCC) or lectin, but we show here another route of tumor cell destruction, that is, some sort of incompletely activated macrophages can kill some type of tumor cells in cooperation with endogenous complement and complment receptors (CR3) without participation of antibody.- Mac-1; complement C3; cytolysisView full abstractDownload PDF (302K) -
HARUHISA FUJITA, TOMONOBU FUJITA, TOSHIHARU SAKURAI, TOSHIHIRO YAMASE, ...1992 Volume 168 Issue 2 Pages 421-426
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSFUJITA, H., FUJITA, T., SAKURAI, T., YAMASE, T. and SETO, Y. Antitumor Activity of New Antitumor Substance, Polyoxomolybdate, against Several Human Cancers in Athymic Nude Mice. Tohoku J. Exp. Med., 1992, 168 (2), 421-426 - Antitumor polyoxomolybdates have been recognized in the course of study on the medical utilization of polyoxometalates, inorganic polymers of metal oxide. [NH3Pri]6 [Mo7O24]•3H2O (PM-8) was found as a representative of antitumor polyoxomolybdates. The growth suppressions of PM-8 against Co-4 human colon cancer xenografted under the subrenal capsule in cd-1 mice were equal or superior to that of 5-FU, MMC, ACMU, ADM and CDDP. Potent antitumor activity of PM-8 is also established against MX-1 human breast and OAT human lung cancer xenografted in athymic nude mice. Polyoxomolybdate is a new type of antitumor substance. - antitumor effect; polyoxomolybdate; human tumor; xenograft; nude mouseView full abstractDownload PDF (496K) -
YUSHI NAKAI, SADAHIRO KOINUMARU, SHUJI SUZUKI, JUNICHI SAITO, SHUNICHI ...1992 Volume 168 Issue 2 Pages 427-430
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSNAKAI, Y., KOINUMARU, S., SUZUKI, S., SAITO, J., SUGAWARA, S., NUMATA, Y., SATO, J., MATSUBARA, N. and MOTOMIYA, M. Chemotherapy in Small Cell Lung Cancer - From View Point of Dose Intensity - Tohoku J. Exp. Med., 1992, 168 (2), 427-430 - Results of chemotherapy trials for small cell lung cancer carried out for the past 5 years were analyzed from view point of dose intensity. Early study of CDDP+EP+ADM (1985 to 1987) showed moderate response rate (RR) of 72% with MST of 369 days. Succeeding alternative protocol of CDDP+EP+ VCR/CPM+ADM+MTX (1989-1990) showed improved RR of 88% and MST of 13 months. Actual dose and interval for the alternating regiman was superior to the single arm regimen. Projected relative dose intensity against MAOP protocol including 6 drugs common to our regimen was 0.86 and delivered RDI was 0.61 with comparable RR and MST. The results may indicate that change of dose intensity within the conventional renge does not result in major advantage or disadvantage for substantial prolongation of the survival in SCLC patients. - small cell lung cancer; chemotherapy; dose intensityView full abstractDownload PDF (421K) -
TETSURO NISHIHIRA, KATSU HIRAYAMA, TAKASHI AKAISHI, RYUZABURO SHINEHA, ...1992 Volume 168 Issue 2 Pages 431-435
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSNISHIHIRA, T., HIRAYAMA, K., AKAISHI, T., SHINEHA, R., OKAYAMA, A. and MORI, S. Which Postoperative Combined Therapy Results in the Best Prognosis: Radiochemocytokine Therapy or Aggressive Chemotherapy? Tohoku J. Exp. Med., 1992, 168 (2), 431-435 - The recurrence of esophageal cancer involving regional nodes, even in patients who have undergone curative surgery, often takes place within three years after surgery. Thus, a new multidisciplinary treatment including cytokines or aggressive chemotherapy with active nutritional support to improve the prognosis in cancer of the thoracic esophagus has been adopted. - aggressive chemotherapy; radiochemocytokine therapy; esophageal cancer; postoperative adjuvant therapy; malignant factorsView full abstractDownload PDF (395K) -
KAZUO KUBOTA, KIICHI ISHIWATA, SUSUMU YAMADA, ROKO KUBOTA, MASAO TADA, ...1992 Volume 168 Issue 2 Pages 437-439
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSKUBOTA, K., ISHIWATA, K., YAMADA, S., KUBOTA, R., TADA, M., SATO, T. and IDO, T. Tumor Radiotherapy Monitoring with Radioscintigraphy Tracers: A Comparative Study with Multiple-Tracer Technique. Tohoku J. Exp. Med., 1992, 168 (2), 437-439 - A comparative multiple-tracer study was performed to assess the tracer feasibility of monitoring tumor radiotherapy. Metabolic tracers for glucose, amino acid, nucleic acid metabolism: F-18-FDG, C-14-Met, H-3-Thd, and F-18-FdUrd and conventional Ga-67 were compared in the same AH109A radiotherapy model using a new quadruple-tracer technique. F-18-FDG showed a large uptake change and a steady response to radiotherapy which is similar to Ga-67. F-18-FdUrd showed a rapid decrease, but the range of change in uptake was narrow. H-3-Thd and C-14-Met showed a rapid response to irradiation and a high sensitivity for monitoring radiotherapy, suggesting that if labeled with C-11, they may be feasible for PET study. - radiotherapy monitoring; tumor scintigraphy; radiopharmaceuticalsView full abstractDownload PDF (231K) -
KATSUYOSHI HORI, MAROH SUZUKI, SHIGERU TANDA, SACHIKO SAITO, QIU-HANG ...1992 Volume 168 Issue 2 Pages 441-443
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSHORI, K., SUZUKI, M., TANDA, S., SAITO, S., ZHANG, Q.-H. and SHINOZAKI, M. Mechanisms for Appearance of No-Flow Areas in Tumor Microvascular Bed. Tohoku J. Exp. Med., 1992, 168 (2), 441-443 - In order to elucidate the mechanism for appearance of no-flow areas (areas where tumor blood flow temporarily cease), we directly observed the process of tumor-induced neovascularization and measured pressure change in a feeding vessel (starting vessel) which supplies blood to the tumor vascular network. Total length of tumor vascular network from one starting vessel increased exponentially as the tumor increased in size exponentially. The pressure of the starting vessel increased from approximately 40cmH2O to 120cmH2O with enlargement of the tumor size. As soon as the pressure of the starting vessel reached a plateau, however, there was a rapid increase in low-flow or no-flow areas in places within the tumor. We considered that no-flow areas were produced by the imbalance between the pressure elevation of a starting vessel and the enlargement of the vascular network from that vessel. - tumor vessel; no-flow area; starting vesselView full abstractDownload PDF (296K) -
SHINICHI OKUYAMA1992 Volume 168 Issue 2 Pages 445-448
Published: 1992
Released on J-STAGE: August 31, 2006
JOURNAL FREE ACCESSOKUYAMA, S. Impacts of the Evolutionary Concepts of Cancer on the Study of Human Diseases. Tohoku J. Exp. Med., 1992, 168 (2), 445-448 - Evolutionary concepts of cancer (Okuyama and Mishina 1984; 1990) have already been found useful in understanding carcinogenesis and anti-cancer defense lines in the body and various cancer attributes. The concept of endosymbiotic disorders gave an impact upon the science of internal medicine leading to discovery of amitosis in Reed-Sternberg cells, a primitive eukaryotism (Okuyama 1991a). A novel concept of vasogenic necrosis was also developed for such diseases of Perthes' disease, cerebral vascular diseases and myocardial infarction: costs of bipedalitic evolution in man. - bipedality; cancer; evolution; Reed-Sternberg cell; vosogenic necrosis syndromeView full abstractDownload PDF (379K)